First Author: M.Onen TURKEY
Co Author(s): Z. Yazar N.I. Ucgun H. Sarikatipoglu 0 0 0 0 0 0 0 0 0
To evaluate the long-term visual outcome after intravitreal anti-vascular endothelial growth factor (VEGF) injections for idiopathic choroidal neovascularization (CNV)
DESIGN: Retrospective observational study.
The medical records of 6 eyes (6 patients) with subfoveal or juxtafoveal idiopathic CNV who were treated with anti-VEGF injections were analyzed. All patients completed at least 2 years of follow-up. Bevacizumab (5 eyes) and ranibuzimab (1 eye) were used as anti-VEGF. All clinical data, including age, best-corrected visual acuity (BCVA, logarithm of the minimal angle of resolution [logMAR]), imaging data of fluorescein angiography, and optical coherence tomography, were investigated.
Mean age was 28.6 ± 9.1 years. During a mean follow-up period of 37.8 ± 8.8 months, a mean of 3.5 ± 1.0 intravitreal anti-VEGF injections were performed. During follow-up, 1 eye (16.6%) showed recurrence. Mean BCVA was 1.06 ± 0.45 logMAR (20/226 Snellen equivalent) at baseline and 0,24 ± 0,14 logMAR (20/34 Snellen equivalent) at 2 years. At 2 years, 4 patients (66.6%) gained 0.3 logMAR or more BCVA than baseline.
Intravitreal anti-VEGF injections showed favorable visual outcomes, and significant visual improvement was maintained in idiopathic CNV patients.